Roche's Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer
Roche announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. This approval makes Erivedge, a capsule taken once-a-day, the first licensed medicine for patients in the European Union with this disfiguring and potentially life-threatening form of skin cancer.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Basal Cell Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Pharmaceuticals | Skin | Skin Cancer